1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>France

French Industry Attacks Price Cut & Drug Shortage Plans

Leem says new stock obligations would add “a new level of complexity”

 
• By Ian Schofield and Dave Wallace

The French government’s plans for more price cuts and new obligations on manufacturers to avert drug shortages will add another layer of complexity to an already complicated operating environment, says the industry.

Scissors_Euros
Price cuts are among a number of measures facing the French industry • Source: Shutterstock

French pharmaceutical industry association Leem has called for a stop to drug price reductions after the government announced plans to impose price cuts totalling €920m as part of wider plans to reduce social security spending.

Leem has also questioned the wisdom of the authorities’ decision to impose new stock obligations on manufacturers as a way of tackling addressing medicine shortages, saying the proposed requirements would

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from France

French Bill Could Improve Clinical Research, But Further Action Is Required

 
• By Francesca Bruce

France’s simplification bill is a “first step” to improving the country’s clinical research environment, but more could be done to drive decentralized trials and simplify processes, says Leem, the French pharmaceutical industry association.

France’s New Carbon Footprint Measuring Method Could Guide Purchasing Decisions

 
• By Francesca Bruce

A new methodology for measuring pharmaceutical company carbon footprints could lead to a single standard for producing these calculations that is applicable to all medicines sold in France, said the industry association, Leem. However, it warned that there remains uncertainty about how the methodology will work in practice.

France Finally Passes Price Cutting Finance Bill – With Some Amendments

 
• By Francesca Bruce

Some changes to the contentious social security financing bill have been made, but industry and the government remain at odds over a €1.2bn drugs overspend.

France Gives Fresh Impetus To Economic Evaluations In Five Year Strategic Plan

 
• By Francesca Bruce

France’s health technology appraisal body, HAS, is putting more emphasis on the importance of economic evaluations in light of the rising costs of health technologies, including medicines and medical devices, and increasing budgetary pressures.

More from Europe

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.

EU Wants Industry To Define ‘Trade Secrets’ Under Health Data Sharing Regulation

 
• By Eliza Slawther

The European Health Data Space Regulation is deliberately “vague” when it comes to defining trade secrets because the EU wants the pharma industry to make recommendations on safeguarding intellectual property, a policy officer for the European Commission says.